Physician profile
Jessica E Smith
NPI 1598137465
$5,820.79
in general payments reported to CMS, 2019-2025
25 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $1,288 · 2023: $1,551 · 2024: $1,373 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,114.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $941.81 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $759.95 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $757.09 | 2021-2024 | Xarelto |
| Terumo Medical Corporation | $577.00 | 2021-2025 | Glidewire, Metacross Otw, Azur Cx Detachable |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.12 | 2021-2025 | Jardiance |
| Abbott Laboratories | $296.52 | 2021-2025 | Pressurewire, Proclaim |
| Medtronic, INC. | $284.55 | 2024-2025 | Hawkone, In.Pact Admiral, Symplicity G3 |
| Heartflow, INC. | $245.21 | 2024-2025 | |
| Edwards Lifesciences Corporation | $240.14 | 2021-2024 | Sapien 3 Ultra Resilia |
| Penumbra, INC. | $207.05 | 2021-2025 | Penumbra System, Indigo System |
| Chiesi USA, INC. | $204.54 | 2023-2025 | Kengreal |
| Cvrx, INC. | $185.17 | 2023 | Barostim Neo System |
| Shockwave Medical, INC | $177.86 | 2022-2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Esperion Therapeutics, INC. | $134.45 | 2022 | |
| Pfizer INC. | $124.97 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $94.97 | 2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $70.69 | 2021-2024 | |
| Janssen Biotech, INC. | $61.52 | 2025 | Tremfya |
| Amgen INC. | $40.34 | 2021-2022 | |
| Almatica Pharma LLC | $22.72 | 2022 | |
| Daiichi Sankyo INC. | $22.34 | 2023 | Injectafer |
| Davol INC. | $20.85 | 2025 | Arista |
| Sandoz INC. | $18.50 | 2023 | Hyrimoz |
| Kestra Medical Technology Services, INC. | $14.78 | 2024 | Assure Wcd |
| Abbvie INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.